RG7440 is primarily utilized in the field of oncology as a therapeutic agent. It functions as a PARP inhibitor, which plays a crucial role in targeting cancer cells, particularly those with BRCA mutations. By inhibiting the PARP enzyme, it prevents the repair of DNA damage in cancer cells, leading to their death. This makes it a valuable component in the treatment of certain types of breast, ovarian, and prostate cancers. Additionally, it is being explored in combination therapies to enhance the efficacy of other cancer treatments, such as chemotherapy and radiation. Its application extends to clinical trials where it is being tested for its potential in treating other forms of cancer and its ability to improve patient outcomes.